Home › Compare › HUMDF vs SBUX

HUMDF vs SBUX: Dividend Comparison 2026

HUMDF yields 484.14% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47899.84M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — HUMDF vs SBUX

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HUMDF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, HUMDF beats the other by $28,951,494,774.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + SBUX for your $10,000?

HUMDF: 50%SBUX: 50%
100% SBUX50/50100% HUMDF
Portfolio after 10yr
$23950.09M
Annual income
$17,030,362,180.03/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
SBUX buys
0
No recent congressional trades found for HUMDF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFSBUX
Forward yield484.14% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$47900.01M ✓$167.0K
Annual income after 10y$34,060,653,223.60 ✓$71,136.45
Total dividends collected$46687.76M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: HUMDF vs SBUX ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$59,114$48,414.43$11,121$420.68+$48.0K → HUMDF
2$330,728$267,475.81$12,548$648.40+$318.2K → HUMDF
3$1,752,431$1,398,551.73$14,440$1,013.98+$1.74M → HUMDF
4$8,800,812$6,925,711.29$17,068$1,617.30+$8.78M → HUMDF
5$41,922,789$32,505,919.38$20,912$2,649.52+$41.90M → HUMDF
6$189,569,894$144,712,509.91$26,875$4,499.29+$189.54M → HUMDF
7$814,403,207$611,563,420.90$36,771$8,014.12+$814.37M → HUMDF
8$3,326,842,984$2,455,431,552.18$54,542$15,197.11+$3326.79M → HUMDF
9$12,933,979,587$9,374,257,594.32$89,602$31,242.49+$12933.89M → HUMDF
10$47,900,011,382$34,060,653,223.60$167,011$71,136.45+$47899.84M → HUMDF

HUMDF vs SBUX: Complete Analysis 2026

HUMDF — Stock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this HUMDF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs OHUMDF vs KOHUMDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.